AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer
Authors:
- Francesca CollinaFCFrancesca Collina
- Lucia La SalaLSLucia La Sala
- Federica LiottiFLFederica Liotti
- Nella PreveteNPNella Prevete
- Elvira La MantiaEMElvira La Mantia
- Maria Grazia ChiofaloMCMaria Grazia Chiofalo
- Gabriella AquinoGAGabriella Aquino
- Laura ArenareLALaura Arenare
- Monica CantileMonica Cantile
- Giuseppina LiguoriGLGiuseppina Liguori
- Francesca Di GennaroFGFrancesca Di Gennaro
- Luciano PezzulloLPLuciano Pezzullo
Open Access
Abstract
Papillary thyroid carcinomas (PTCs) have an excellent prognosis, but a fraction of them show aggressive behavior, becoming radioiodine (RAI)-resistant and/or metastatic. AXL (Anexelekto) is a tyrosine kinase receptor regulating viability, invasiveness and chemoresistance in various human cancers, including PTCs. Here, we analyze the role of AXL in PTC prognosis and as a marker of RAI refractoriness. Immunohistochemistry was used to assess AXL positivity in a cohort of human PTC samples. Normal and cancerous thyroid cell lines were used in vitro for signaling, survival and RAI uptake evaluations. 38.2% of human PTCs displayed high expression of AXL that positively correlated with RAI-refractoriness and disease persistence or recurrence, especially when combined with v-raf murine sarcoma viral oncogene homolog B(BRAF) V600E mutation. In human PTC samples, AXL expression correlated with V-akt murine thymoma viral oncogene homolog 1 (AKT1) and p65 nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) activation levels. Consistently, AXL stimulation with its ligand growth arrest-specific gene 6 (GAS6) increased AKT1- and p65 NF-kB-phosphorylation and promoted survival of thyroid cancer cell lines in culture. Enforced expression or activation of AXL in normal rat thyroid cells significantly reduced the expression of the sodium/iodide symporter (NIS) and the radioiodine uptake. These data indicate that AXL expression levels could be used as predictor of RAI refractoriness and as a possible novel therapeutic target of RAI resistant PTCs.Keywords
This publication has 50 references indexed in Scilit:
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive DiseaseJournal of Thyroid Research, 2012
- Axl is essential for VEGF‐A‐dependent activation of PI3K/AktThe EMBO Journal, 2012
- Molecular genetics and diagnosis of thyroid cancerNature Reviews Endocrinology, 2011
- Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcomaBlood, 2010
- A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancerJournal of Cell Science, 2009
- The cancer genomeNature, 2009
- The human receptor tyrosine kinase Axl gene – promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylationBioscience Reports, 2008
- Exploring the specificity of the PI3K family inhibitor LY294002Biochemical Journal, 2007
- Expression of the Sodium Iodide Symporter and Thyroglobulin Genes Are Reduced in Papillary Thyroid CancerLaboratory Investigation, 2001